The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

por Barber, Emma L., Zsiros, Emese, Lurain, John R., Rademaker, Alfred, Schink, Julian C., Neubauer, Nikki L.
Publicado 2013

Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium

por Barber, Emma L., Chen, Siqi, Pineda, Mario Javier, Robertson, Sharon E., Hill, Emily K., Teoh, Deanna, Schilder, Jeanne, O'Shea, Kaitlyn L., Kocherginsky, Masha, Zhang, Bin, Matei, Daniela
Publicado 2022

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study

por Ghezelayagh, Talayeh S., Wu, Emily S., Barber, Emma L., Dao, Minh D., Zsiros, Emese, Urban, Renata R., Gray, Heidi J., Goff, Barbara A., Shah, Chirag A., Neubauer, Nikki L., Dai, James Y., Tanyi, Janos L., Liao, John B.
Publicado 2023